These results strongly support further development acceleration
VLA1553 was generally safe in all dose groups
- Well-tolerated in the low and medium dose. (Superior safety profile, including viremia, compared to the high dose group)
- Excellent local tolerability
Excellent immunogenicity profile in all dose groups after a single vaccination
- 100% Seroconversion1 achieved at Day 14 after a single vaccination in all dose groups
- Sustained at 100% after six months
Saint Herblain (France), May 22, 2019 – Valneva SE (“Valneva” or “the Company”), a biotech company developing and commercializing vaccines for infectious diseases with major unmet medical needs, today announced further positive Phase 1 results for its chikungunya vaccine candidate, VLA1553.